Combination antagonist angiopoietin-2 and VEGF-A antagonist, and / or KDR, and / or Flt1 for cancer treatment

摘要

A combination of an antibody antagonist of the biological activity of Angiopoietin-2, which inhibits UNION Ang-2 / Tie-2, and an antagonist of the biological activity of: I. VEGF-A, and / or II. KDR, and / or III. Flt1. wherein the antagonist of Angiopoietin antibody-2 is an antibody comprising: (a) a VH region having at least 95% identity with the amino acid sequence of SEQ ID NO. 6; and (b) a VL region having at least 95% identity with the amino acid sequence of SEQ ID NO. 8 and